Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-dose and food-effect study of M875 in healthy Japanese males
jRCT2071240065Phase 1Completed
- Sponsor
- Medisa Shinyaku
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of apremilast in oral lichen planus (OLP) (4 arms), sponsored by Medisa Shinyaku. Primary endpoints: Pharmacokinetics of M875 and components and Safety and tolerability. Started Oct 2024; status: completed.
02
Drugs
apremilast
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on jRCT2071240065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240065.